Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678277 | 1.00 | GLO1 (0.50) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL2357523 | 1.00 | GLO1 (0.50) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL223388 | 0.90 | ALDH1A1 (0.50) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL17827812 | 0.87 | GLO1 (0.56) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL4519435 | 0.87 | ALDH1A1 (0.52) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL1085142 | 0.86 | GLO1 (0.47) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL1085140 | 0.86 | GLO1 (0.47) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL1085139 | 0.86 | GLO1 (0.47) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL9794499 | 0.84 | ALDH1A1 (0.44) | GLO1ALDH1A1LMNAHSD17B10ALOX15 | |
| SCHEMBL9794502 | 0.84 | ALDH1A1 (0.44) | GLO1ALDH1A1LMNAHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-8680104-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1734966-B1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295912-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2012-11-22 | — | — | US | disclosed |
| US-8268826-B2 | 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV | INCYTE CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| EP-1734966-A4 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080009622-A1 | METHOD FOR PRODUCING PYRIMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2008-01-10 | — | — | US | disclosed |
| US-7161024-B2 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161024-B2 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161024-B2 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1734966-A2 | PIPERIZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | Incyte Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1644313-A2 | PROCESS FOR THE PREPARATION AND PURIFICATION OF 2-(ALKOXYALKYLIDENE)-3-KETOALKANOIC ACID ESTERS FROM 3-KETOALKANOIC ACID ESTERS | SCHERING CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005101838-A2 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050027140-A1 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007608-A2 | PROCESS FOR THE PREPARATION AND PURIFICATION OF 2-(ALKOXYALKYLIDENE)-3-KETOALKANOIC ACID ESTERS FROM 3-KETOALKANOIC ACID ESTERS | SCHERING CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004067513-A1 | ANTAGONISTS FOR ALPHA-2 ADRENOCEPTORS | OY JUVANTIA PHARMA LTD (FI) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027140-A1 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | ACKR3, CCR5, CCRL2 | GLO1 3455/4885ALDH1A1 437/4885LMNA 3977/4885 |
| US-20080009622-A1 | METHOD FOR PRODUCING PYRIMIDINE COMPOUND | TYMS, TYMP, UMPS | GLO1 2527/4885ALDH1A1 1676/4885LMNA 3372/4885 |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | CCR5, CCR2, CXCR5 | GLO1 4872/4885ALDH1A1 1435/4885LMNA 4812/4885 |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | GLO1 4872/4885ALDH1A1 1435/4885LMNA 4812/4885 |
| US-20120295912-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | GLO1 4872/4885ALDH1A1 1435/4885LMNA 4812/4885 |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | GLO1 4872/4885ALDH1A1 1435/4885LMNA 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.